Cargando…

Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model

BACKGROUND: Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by 10% compared to post- dialysis concentrations....

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Satoshi, Yoshikawa, Shinichi, Sato, Akira, Matsumoto, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644586/
https://www.ncbi.nlm.nih.gov/pubmed/37957772
http://dx.doi.org/10.1186/s40780-023-00307-9
_version_ 1785147260116402176
author Yoshikawa, Satoshi
Yoshikawa, Shinichi
Sato, Akira
Matsumoto, Tsukasa
author_facet Yoshikawa, Satoshi
Yoshikawa, Shinichi
Sato, Akira
Matsumoto, Tsukasa
author_sort Yoshikawa, Satoshi
collection PubMed
description BACKGROUND: Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by 10% compared to post- dialysis concentrations. However, the material of the dialysis membrane remains unknown. In addition, there have been no reports on the effects of continuous hemodiafiltration. In this study, we investigated the effects of continuous hemodiafiltration on tedizolid using two types of dialysis membranes made of different materials. METHODS: The adsorption of tedizolid, linezolid, and vancomycin to two different dialysis membranes was investigated, and the clearance of each drug was calculated by experiments using an in vitro continuous hemodiafiltration model. RESULTS: The adsorption of tedizolid, linezolid, and vancomycin on the dialysis membranes was examined, and no adsorption was observed. Experimental results from the continuous hemodiafiltration model showed that linezolid and vancomycin concentrations decreased over time: after two hours, the respective decreases were 26.48 ± 7.14% and 28.51 ± 2.32% for polysulfone membranes, respectively. The decrease was 23.57 ± 4.95% and 28.73 ± 5.13% for the polymethylmethacrylate membranes, respectively. These results suggested that linezolid and vancomycin were eliminated by continuous hemodiafiltration. In contrast, tedizolid phosphate and tedizolid concentrations decreased slightly in the polysulfone and polymethylmethacrylate membranes. The decrease in concentrations were 2.10 ± 0.77% and 2.97 ± 0.60% for the polysulfone membranes, respectively. For the polymethylmethacrylate membranes, the decrease in concentration were 2.01 ± 0.88% and 1.73 ± 0.27%, respectively. CONCLUSION: These results suggested that tedizolid should not be considered for dose control during continuous hemodiafiltration.
format Online
Article
Text
id pubmed-10644586
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106445862023-11-14 Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model Yoshikawa, Satoshi Yoshikawa, Shinichi Sato, Akira Matsumoto, Tsukasa J Pharm Health Care Sci Research Article BACKGROUND: Tedizolid is an oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by 10% compared to post- dialysis concentrations. However, the material of the dialysis membrane remains unknown. In addition, there have been no reports on the effects of continuous hemodiafiltration. In this study, we investigated the effects of continuous hemodiafiltration on tedizolid using two types of dialysis membranes made of different materials. METHODS: The adsorption of tedizolid, linezolid, and vancomycin to two different dialysis membranes was investigated, and the clearance of each drug was calculated by experiments using an in vitro continuous hemodiafiltration model. RESULTS: The adsorption of tedizolid, linezolid, and vancomycin on the dialysis membranes was examined, and no adsorption was observed. Experimental results from the continuous hemodiafiltration model showed that linezolid and vancomycin concentrations decreased over time: after two hours, the respective decreases were 26.48 ± 7.14% and 28.51 ± 2.32% for polysulfone membranes, respectively. The decrease was 23.57 ± 4.95% and 28.73 ± 5.13% for the polymethylmethacrylate membranes, respectively. These results suggested that linezolid and vancomycin were eliminated by continuous hemodiafiltration. In contrast, tedizolid phosphate and tedizolid concentrations decreased slightly in the polysulfone and polymethylmethacrylate membranes. The decrease in concentrations were 2.10 ± 0.77% and 2.97 ± 0.60% for the polysulfone membranes, respectively. For the polymethylmethacrylate membranes, the decrease in concentration were 2.01 ± 0.88% and 1.73 ± 0.27%, respectively. CONCLUSION: These results suggested that tedizolid should not be considered for dose control during continuous hemodiafiltration. BioMed Central 2023-11-14 /pmc/articles/PMC10644586/ /pubmed/37957772 http://dx.doi.org/10.1186/s40780-023-00307-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yoshikawa, Satoshi
Yoshikawa, Shinichi
Sato, Akira
Matsumoto, Tsukasa
Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model
title Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model
title_full Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model
title_fullStr Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model
title_full_unstemmed Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model
title_short Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model
title_sort poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644586/
https://www.ncbi.nlm.nih.gov/pubmed/37957772
http://dx.doi.org/10.1186/s40780-023-00307-9
work_keys_str_mv AT yoshikawasatoshi poorremovaloftedizolidduringcontinuoushemodiafiltrationexperimentsusinganinvitrocontinuoushemodiafiltrationmodel
AT yoshikawashinichi poorremovaloftedizolidduringcontinuoushemodiafiltrationexperimentsusinganinvitrocontinuoushemodiafiltrationmodel
AT satoakira poorremovaloftedizolidduringcontinuoushemodiafiltrationexperimentsusinganinvitrocontinuoushemodiafiltrationmodel
AT matsumototsukasa poorremovaloftedizolidduringcontinuoushemodiafiltrationexperimentsusinganinvitrocontinuoushemodiafiltrationmodel